INDIGO-Com: INvestigating DIGital Outcomes in the Community

Sponsor
Imperial College London (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06095024
Collaborator
Imperial College Healthcare NHS Trust (Other)
20,000
1
18
1110.9

Study Details

Study Description

Brief Summary

To explore the feasibility and best methodology for collecting patient-reported outcome measures in patients who have previously been treated for cancer and are living in the community.

The investigators are working with primary care research teams, and using an online electronic questionnaire. Although the study is entirely observational, the study offers some of the questions in a random order, so the investigators can explore the effect of changing the way in which questions are asked.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    INDIGO Community aims to both collect data on patient-reported outcome measures (PROMS) and patient-reported experience measures (PREMS) and data on the impact of how to do this.

    The focus is on adult patients living in the community who have previously been treated for cancer.

    The study uses a range of quality of life questionnaires, and randomises the order in which some questions are asked, in order to explore the impact of how questions are asked on responses.

    All patients with be offered the EuroQol 5 dimension, 5 level questionnaire (EQ5D-5L)

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    20000 participants
    Observational Model:
    Ecologic or Community
    Time Perspective:
    Prospective
    Official Title:
    INDIGO Community Participant Led Electronic Completion of PROMs and PREMs for Patients Living With and Beyond Cancer in the Community
    Anticipated Study Start Date :
    Dec 1, 2023
    Anticipated Primary Completion Date :
    Dec 31, 2024
    Anticipated Study Completion Date :
    Jun 1, 2025

    Arms and Interventions

    Arm Intervention/Treatment
    Linked to national data

    Patients will be randomly assigned to be asked to link personal data with national cancer data. The outcome measure will be the proportion of completed questionnaires

    Linking to national data, early vs. late questions

    Subset of cohort 1: Patients will be randomly assigned to be asked the question about data linkage at the beginning vs. end of the questionnaire The outcome measure will be the proportion answering yes in each arm

    Different PROM Completion rate

    Patients will be randomised to two different PROM questionnaires The outcome measure will be the completion rate of the two different questionnaires

    Impact of additional PROMS on completion and satisfaction

    Patients will be randomised to either a standard PROM or additional, symptom directed questionnaire The outcome measure will be the satisfaction rate of patients in each arm

    Outcome Measures

    Primary Outcome Measures

    1. Completion of study questionnaire [12 months]

      Proportion of patients completing the entire study questionnaire

    2. Agreement to link to national cancer data [12 months]

      Proportion of patients agreeing to link their data to national cancer data

    Secondary Outcome Measures

    1. Completion of PROMs questionnaires [12 months]

      Proportion of patients completing PROMS questionnaires

    2. Satisfaction with questionnaires [12 months]

      Patient-reported satisfaction with questionnaires, expressed as average scores (on a scale of 1 - 10, where 10 is better) and proportion scoring 5 or over

    3. Effectiveness of different communication channels for recruitment [12 months]

      Enrolment rate via different recruitment channels (Primary Care Research Network, Social Media) expressed as the proportion of patient recruited via each channel

    4. Correlation of each PROM score with quality of life [12 months]

      Correlation of each PROM score with the EuroQol 5 Dimensions, 5 levels (EQ5D-5L) quality of life measure

    Other Outcome Measures

    1. The feasibility of developing a national longitudinal cohort [12 months]

      To assess what proportion of participants agree to ongoing, long-term follow-up

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    16 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • Anyone over the age of 16 who has been diagnosed (receiving treatment is not an inclusion criteria although the investigators expect as this is a long-term survivorship study all participants will have received treatment) for any type of cancer in the past (> 12 months) can participate.

    • Participants who self-identify as having previously (time unlimited) received a diagnosis of cancer, based on histological, radiological, or clinical grounds (primary and/or metastatic cancer). Current treatment is not a barrier to participation, but the emphasis is on patients who have completed treatment.

    Participants need to be able to access the secure online platform, using a mobile device or computer.

    • Have capacity and be able to provide informed consent via the online platform.

    • To be able to understand, read and write English, with or without support from a trusted individual e.g., friends, family, carer.

    Exclusion Criteria:
    • Participants recently diagnosed with cancer (less than 12 months ago).

    • Participants unable to access secure online platform.

    • Participants who do not have sufficiently good understanding of written English to complete the PROMs and are unable to be supported by a trusted individual to complete the questionnaire.

    • Participants lacking capacity and unable to give informed consent.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Imperial College Healthcare NHS Trust London United Kingdom W6 8RF

    Sponsors and Collaborators

    • Imperial College London
    • Imperial College Healthcare NHS Trust

    Investigators

    • Principal Investigator: Matthew Williams, MBChB PhD FRCR, Imperial College Healthcare Trust

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Imperial College London
    ClinicalTrials.gov Identifier:
    NCT06095024
    Other Study ID Numbers:
    • 000000
    First Posted:
    Oct 23, 2023
    Last Update Posted:
    Oct 23, 2023
    Last Verified:
    Oct 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Oct 23, 2023